Abstracts tagged "Hydroxychloroquine"

Abstract Number: 2635 • 2017 ACR/ARHP Annual Meeting
Dosechecker: Solving the Hydroxychloroquine Dosing Dilemma with a Smart Phone App
Elliot Perlman¹, Robert Friday², Paul Greenberg³, David Browning⁴ and Joan Miller⁵, ¹Rhode Island Eye Institute, Providence, RI, ²Division of Rheumatology, Department of Medicine, Newton-Wellesley Hospital, Newton, MA, ³Division of Ophthalmology, Alpert Medical School, Brown University, Providence, RI, ⁴Charlotte Eye Ear, Nose, and Throat Associates, Charlotte, NC, ⁵Department of Ophthalmology, Harvard Medical School and Massachusetts Eye and Ear Institute, Boston, MA
Background/Purpose: Hydroxychloroquine retinopathy (HCR) is a potentially blinding but largely preventable disease. The true prevalence of HCR is unknown among the 350,000 Americans who take…
Abstract Number: 442 • 2017 ACR/ARHP Annual Meeting
Early Treatment with Hydroxychloroquine Is Associated with Better Long-Term Outcomes in a Group of Hispanic Patients with Rheumatoid Arthritis
Franchesca Cruz-Pérez¹, Mariangelí Arroyo-Ávila¹, Ruth Fred-Jiménez², Naydi Pérez-Ríos³, Noelia Rodríguez-Pérez¹, Grissel Ríos⁴ and Luis M. Vilá⁵, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ³Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁴Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ⁵Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) has a disease-modifying effect in rheumatoid arthritis (RA) patients but also it is associated with improved lipid profile, and decreased risk for…
Abstract Number: 1296 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine Level Decreases throughout Pregnancy: Implications for Maternal and Neonatal Outcomes
Stephen Balevic¹, Michael Cohen-Wolkowiez², Amanda M. Eudy³, Laura E. Schanberg⁴ and Megan E. B. Clowse⁵, ¹Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC, ²Pharmacometrics Center, Duke Clinical Research Institute, Durham, NC, ³Duke University Medical Center, Chapel Hill, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Pregnancies in women with active rheumatic disease often result in poor neonatal outcomes. Prior data suggests that hydroxychloroquine (HCQ) can reduce disease activity and…
Abstract Number: 1297 • 2017 ACR/ARHP Annual Meeting
Hydroxychloroquine in Lupus Pregnancy: A Meta-Analysis of Individual Participant Data
Amanda M. Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Mokbel⁴, Cecilia Nalli⁵, Laura Andreoli⁵, Angela Tincani⁶, Yair Molad⁷, Stephen Balevic⁸ and Megan E. B. Clowse¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology and Hiller Research Unit, University Hospital Duesseldorf, Duesseldorf, Germany, ⁴Department of Rheumatology and Rehabilitation, Cairo University Hospital, Cairo, Egypt, ⁵Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁶Spedali Civili and University of Brescia, Brescia, Italy, ⁷Rheumatology Unit, Rabin Medical Center, Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁸Rheumatology, Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Our current knowledge about how to treat lupus in pregnancy derives from small prospective or retrospective cohorts, and how best to manage lupus nephritis…
Abstract Number: 1651 • 2017 ACR/ARHP Annual Meeting
Screening in Patients at High Risk of Hydroxychloroquine Retinal Toxicity
Anna Viola Taulaigo¹, Maria Francisca Moraes-Fontes¹, Eunice Patarata², Sara Guerreiro Castro² and Arnaldo Dias-Santos³, ¹Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central, Lisbon, Portugal, ²Unidade de Doenças Auto-imunes, Hospital Curry Cabral, Centro Hospitalar de Lisboa Central (CHLC), Lisbon, Portugal, Lisbon, Portugal, ³Serviço de Oftalmologia, Hospital de Santo António dos Capuchos, CHLC, Lisbon, Portugal, Lisbon, Portugal
Background/Purpose: Despite effectiveness and favourable safety profile, antimalarials have the potential to cause irreversible macular retinopathy and vision loss. Screening methods still vary among clinicians…
Abstract Number: 1964 • 2017 ACR/ARHP Annual Meeting
The Risk of Hydroxychloroquine Toxic Retinopathy and Its Risk Factors in the Treatment of Rheumatic Diseases: A Systematic Review
April Jorge¹, Sharan K. Rai² and Hyon K. Choi², ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. While generally well-tolerated and…
Abstract Number: 751 • 2016 ACR/ARHP Annual Meeting
Complement C4d Split Products on Erythrocytes Are Associated with Composite Measure of Disease Activity in Systemic Lupus Erythematosus Subjects Receiving Methotrexate and Hydroxychloroquine
Michelle Petri¹, Ying Qu², John Conklin³, Kelley Brady⁴, Robert Apilado⁵ and Thierry Dervieux⁶, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴R&D, Exagen Diagnostics, Vista, CA, United Kingdom, ⁵Exagen Diagnostics, vista, CA, United Kingdom, ⁶Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: We evaluated the relationships between disease activity measures and C4d split products on erythrocytes (EC4d) in SLE subjects from a subset of the Hopkins…
Abstract Number: 752 • 2016 ACR/ARHP Annual Meeting
Anti-Ro Positivity Is a Predictor of Responsiveness to Topical Steroids or Hydroxychloroquine in Patients with Discoid but Not Subacute Cutaneous Lupus
Rajaie Namas¹, Corey Powell² and J. Michelle Kahlenberg³, ¹Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ²Consulting for Statistics, Computing and Analytics Research, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) lesions are difficult to treat and medications are often chosen based only on provider experience. Thus, we chose to assess…
Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting
Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Claire Rempenault¹, Thomas Barnetche², Jacques Morel³, Cédric Lukas⁴, Cécile Gaujoux-Viala⁵, Bernard Combe⁶ and Charlotte Hua⁷, ¹Rheumatology, CHU Lapeyronie, University of Montpellier, France, ²Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, ³Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ⁴Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁵Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, ⁶Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Karen Ferez-Blando¹, Hilda Fragoso-Loyo², Alfredo Ponce de León³, Sergio Ponce de Leon-Rosales⁴ and Yemil Atisha-Fregoso¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…
Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach
Wei Fu¹ and Michelle Petri², ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
Abstract Number: 2047 • 2016 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Adey Berhanu³, Cesar Fors-Nieves⁴, Ummara Shah⁵, Patrick Brown⁶, Carl Laskin⁷, Nathalie Morel⁸, Kateri Levesque⁹, Jill P. Buyon¹⁰, Earl Silverman⁶ and Peter M. Izmirly¹¹, ¹Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ²Internal Medicine, Cochin University Hospital, Paris, France, ³Rheumatology Fellowship Program, NYU Langone Medical Center/NYU School of Medicine, New York, NY, ⁴Division of Rheumatology, NYU School of Medicine, New York, NY, ⁵Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁶University of Toronto, Toronto, ON, Canada, ⁷Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁸Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁹Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ¹⁰Medicine, Tisch Hospital, New York, NY, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Histopathologic studies of cutaneous neonatal lupus erythematosus (cNLE) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in…
Abstract Number: 2322 • 2016 ACR/ARHP Annual Meeting
The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle
Thomas Khoo¹, Sophia Otto², Barbara Koszyka², Caroline Smith², Peter Blumbergs³, Sue Lester⁴ and Vidya Limaye⁵, ¹Medical Student, University of Adelaide, Adelaide, Australia, ²Anatomical Pathology, SA Pathology, Adelaide, Australia, ³Pathology, University of Adelaide, Adelaide, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: The electronic database of muscle biopsies reported in the Anatomical Pathology Laboratory, SA Pathology was searched from 2006 to the present, to identify biopsies…
Abstract Number: 2433 • 2016 ACR/ARHP Annual Meeting
Trends in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012
Bonnie L. Bermas¹, Seoyoung Kim^2,3, Krista Huybrechts⁴, Sonia Hernandez-diaz⁵, Brian T. Bateman⁶ and Rishi J. Desai⁷, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Harvard School of Public Health, Boston, MA, ⁶Division of Pharmacoepidemiology and Pharocoeconomics, Brigham and Women's Hospital, Boston, MA, ⁷PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA
Background/Purpose : Data suggest that hydroxychloroquine (HCQ) use during systemic lupus erythematosus (SLE) pregnancies improves outcomes. In the past decade, single-center studies report that a…
Abstract Number: 2453 • 2016 ACR/ARHP Annual Meeting
The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
Megan E. B. Clowse¹, Amanda M. Eudy², Bonnie L. Bermas³, Eliza Chakravarty⁴, Lisa R. Sammaritano⁵ and Christina D. Chambers⁶, ¹Rheumatology, Duke University School of Medicine, Durham, NC, ²Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Edmond, OK, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Pediatrics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are presently no official guidelines about the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro antibodies. The objective…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].